CervoMed Inc. (CRVO) is a Healthcare · Biotechnology company listed on NASDAQ. Price $2.43 (-4.71%), Market cap $0.03B, 52-week low–high $2.89 ~ $10.69.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood"brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered
Financial statements, price targets, institutional (13F) holdings and related news for CervoMed Inc. are updated in real time on BlackAll Trade.
CervoMed Inc. trades at $2.43 (-4.71%). Real-time quotes and charts are available on BlackAll Trade.
CervoMed Inc. has a market cap of about $0.03B.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an o